ENTX - Entera Bio Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Entera Bio Ltd.

Minrav Building
Fifth Floor Kiryat Hadassah PO Box 12117
Jerusalem 9112002
Israel
972 2 532 7151
http://www.enterabio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Dr. Phillip Schwartz Ph.D.CEO & Director362.56kN/A1962
Dr. Hillel GalitzerChief Operating Officer235.67kN/A1978
Dr. Roger J. GarceauChief Devel. Advisor & Director108.92kN/A1954
Dr. Arthur C. Santora IIChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.

Corporate Governance

Entera Bio Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.